Exhaled leukotriene B4 and community acquired pneumonia in children

S. Carraro, B. Andreola, L. Da Dalt, S. Callegaro, R. Alinovi, C. Corradi, E. Baraldi (Padova, Parma, Italy)

Source: Annual Congress 2006 - Pneumonia and other invasive pulmonary infections in children
Session: Pneumonia and other invasive pulmonary infections in children
Session type: Poster Discussion
Number: 1795

Congress or journal article abstract

Abstract

Rationale: The alveolar infiltrate in pneumonia is characterized by a high number of activated neutrophils, for which leukotriene B4 (LTB4) is a strong activating and chemotactic agent. Exhaled breath condensate (EBC) is a safe and non-invasive technique that allows the study of lower airways. The present study was conducted to measure EBC LTB4 as a potential non-invasive marker of the inflammatory response which occurs in community acquired pneumonia (CAP).
Methods: 11 children with CAP were recruited. They underwent physical examination, chest X-ray and a blood sample was drawn to measure leukocyte count and C-reactive protein. Moreover, children performed spirometry and EBC collection using a refrigerating system supplied with disposable device (Turbo DECCS, Parma, Italy). EBC collection and spirometry were repeated after one week of antibiotic therapy and one month later. LTB4 levels were assessed using an EIA system (Amersham Biosciences).
Results: LTB4 EBC concentrations were increased in the acute phase of CAP (mean + SEM: 14.8 + 2.0 pg/ml) and decreased significantly after one week of antibiotic therapy (6.0 + 1.4 pg/ml, p<0.001). No further reduction was demonstrated one month later (5.4 + 1.7 pg/ml, p=ns). Spirometry demonstrated a restrictive pattern in the acute phase (mean FEV1 67% pred, mean FVC 65% pred) and improved significantly one week later (mean FEV1 81% pred, mean FVC 81% pred, p<0.01).
Conclusion: LTB4 concentrations are increased in EBC of children with CAP and decrease after a course of antibiotic therapy. Our findings suggest that LTB4 is involved in the inflammatory response which characterizes CAP. EBC may represent a new approach to study the pathophysiology of deep lung infections.


Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Carraro, B. Andreola, L. Da Dalt, S. Callegaro, R. Alinovi, C. Corradi, E. Baraldi (Padova, Parma, Italy). Exhaled leukotriene B4 and community acquired pneumonia in children. Eur Respir J 2006; 28: Suppl. 50, 1795

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Increased exhaled cysteinyl-leukotrienes, leukotriene B4 and 8-isoprostane in exacerbation of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 248s
Year: 2001

Cysteinyl leukotrienes and leukotriene B4 in expired breath condensate in patients with chronic asthma treated with montelukast
Source: Eur Respir J 2003; 22: Suppl. 45, 101s
Year: 2003

Urinary leukotriene E4 and exhaled nitric oxide on recovery from exercise-induced bronchospasm in asthmatic children
Source: Eur Respir J 2006; 28: Suppl. 50, 259s
Year: 2006

Leukotriene B4 levels in sputum from asthma patients
Source: ERJ Open Res, 2 (4) 00088-2015; 10.1183/23120541.00088-2015
Year: 2016



Corticosteroid reversibility testing and exhaled leukotriene B4 in patients with stable, severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 252s
Year: 2002

Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia
Source: Eur Respir J 2008; 32: 437-442
Year: 2008



Leukotriene B4 in exhaled breath condensate of patients after lung transplantation
Source: Eur Respir J 2001; 18: Suppl. 33, 297s
Year: 2001

Saliva is one likely source of leukotriene B4 in exhaled breath condensate
Source: Eur Respir J 2006; 28: 1229-1235
Year: 2006



Therapeutical impact of montelukast on exhaled leukotrienes in asthmatic children
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006

Exhaled leukotrienes B4 and E4 in nonasthmatic patients with seasonal allergic rhinitis in and out of the pollen season
Source: Eur Respir J 2005; 26: Suppl. 49, 372s
Year: 2005

Exhaled nitric oxide and airway resistance in preschool children with and without respiratory symptoms
Source: Annual Congress 2008 - Wheezing in preschool children
Year: 2008


Eosinophil activation and cysteinyl leukotriene production in infants with RSV positive bronchiolitis
Source: Eur Respir J 2001; 18: Suppl. 33, 180s
Year: 2001

Leukotriene B4 in breath condensate in patients with exacerbation of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 248s
Year: 2001

Exhaled nitric oxide increases in chronic eosinophilic pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 509s
Year: 2002

Exhaled nitric oxide and serum IgE in children admitted to a pediatric department
Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases
Year: 2012

Exhaled leukotrienes in smoking and non-smoking patients with chronic asthma
Source: Annual Congress 2006 - Smoking asthmatics – a neglected population?
Year: 2006


Thromboxane B2 and prostaglandin E2 concentrations in exhaled breath condensate in healthy volunteers and patients with bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 509s
Year: 2002

Exhaled nitric oxide levels during upper respiratory infections (URI) in young patients with rinasma
Source: Eur Respir J 2001; 18: Suppl. 33, 164s
Year: 2001

Exhaled nitric oxide in children with severe asthma
Source: Annual Congress 2012 - Severe asthma and developing allergy in childhood
Year: 2012


Relationship betweeen exhaled nitric oxide and clinical pattern in Community-acquired pneumonia patients
Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia
Year: 2017